Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus

Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus

The Cigna Group (CI) has successfully executed a unique, highly focused strategic pivot among the major managed care organizations. By systematically shedding volatile, government-sponsored segments and focusing on commercial employer-sponsored plans and high-margin pharmacy services under Evernorth, Cigna has insulated itself from the severe Medicare Advantage and Medicaid margin compression affecting its peers.

The Q1 2026 Financial Engine and ACA Exchange Exit

In its Q1 2026 financial results reported on April 30, 2026, Cigna beat Wall Street expectations, posting net income of $1.65 billion on $68.49 billion in revenue, representing a 29.1% year-over-year earnings increase. Over the trailing twelve months, Cigna generated $277.89 billion in revenue with an operating margin of 5.5% and a net profit margin of 2.3%.

Crucially, Cigna announced a complete exit from the Affordable Care Act (ACA) individual exchanges, effective at the end of 2026. This exit will phase out plans for 369,000 members across 11 states. This follows Cigna's exit from the Medicare Advantage market in 2025 via the sale of its Medicare business to Health Care Services Corporation (HCSC). By exiting both federal insurance programs, Cigna has successfully de-risked its book of business from rising medical utilization and federal subsidy expirations.¹

The strategic benefit of this de-risking is visible in Cigna Healthcare’s Medical Loss Ratio (MLR), which fell to an impressive 79.8% in Q1 2026, down from 82.2% in the prior year quarter.

Strategic Review and Potential Divestiture of eviCore

In tandem with its switch in leadership—as incoming CEO Brian Evanko prepares to succeed long-time chief David Cordani in summer 2026—Cigna has initiated a formal review of strategic alternatives, including a potential sale or partnership, for eviCore, its utilization and care management subsidiary.

This move is a proactive response to escalating regulatory and public relations scrutiny surrounding prior authorization practices. Critics and investigative reports have accused care review platforms like eviCore of generating profits primarily by delaying or denying medical payments. By exploring a divestiture of eviCore, Cigna aims to offload a major source of public and regulatory friction while freeing up capital to double down on its core growth engines: specialty pharmacy services and employer-sponsored plans.

"Cigna is exiting the Affordable Care Act exchanges — and exploring a sale of its controversial claims review subsidiary — as the company continues to prune its portfolio to focus on pharmacy services and employer-sponsored plans." — Healthcare Dive, April 30, 2026

"Cigna underwent a fresh portfolio review in tandem with its chief executive switch — CEO David Cordani is leaving this summer after almost two decades at the company’s helm — and its ACA plans and EviCore fell short..." — Healthcare Dive, April 30, 2026